Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Synovus Financial Corp

Synovus Financial Corp lifted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 71.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 163,893 shares of the biotechnology company’s stock after purchasing an additional 68,389 shares during the quarter. Synovus Financial Corp owned approximately 0.18% of Rocket Pharmaceuticals worth $2,060,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Covestor Ltd lifted its stake in Rocket Pharmaceuticals by 33,166.7% in the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 1,990 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Rocket Pharmaceuticals by 222.6% in the 4th quarter. Kennedy Capital Management LLC now owns 38,208 shares of the biotechnology company’s stock valued at $480,000 after acquiring an additional 26,365 shares during the period. Raymond James Financial Inc. purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at $285,000. Renaissance Technologies LLC purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at $2,747,000. Finally, Legal & General Group Plc boosted its stake in Rocket Pharmaceuticals by 3.3% during the 4th quarter. Legal & General Group Plc now owns 75,454 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 2,416 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Trading Up 10.5 %

NASDAQ:RCKT opened at $6.53 on Wednesday. Rocket Pharmaceuticals, Inc. has a 1 year low of $4.55 and a 1 year high of $26.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The stock has a fifty day moving average price of $8.19 and a two-hundred day moving average price of $11.92. The stock has a market capitalization of $696.29 million, a price-to-earnings ratio of -2.37 and a beta of 1.00.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.06. As a group, sell-side analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah bought 20,000 shares of the stock in a transaction on Thursday, April 10th. The shares were bought at an average price of $5.08 per share, with a total value of $101,600.00. Following the completion of the acquisition, the chief executive officer now owns 792,680 shares of the company’s stock, valued at approximately $4,026,814.40. This trade represents a 2.59 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kinnari Patel purchased 21,099 shares of the business’s stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $4.70 per share, with a total value of $99,165.30. Following the purchase, the insider now directly owns 26,774 shares in the company, valued at approximately $125,837.80. The trade was a 371.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on RCKT. Chardan Capital dropped their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 price objective for the company. Canaccord Genuity Group decreased their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reissued a “buy” rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, April 9th. Finally, BMO Capital Markets initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target for the company. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.00.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.